Daewoong Pharmaceutical Expands Global Collaboration on Microneedles and Biosimilars

Full-scale Launch of New Businesses at CPHI 2025

Daewoong Pharmaceutical announced on the 5th that it participated in the world's largest pharmaceutical and biotechnology exhibition, "2025 CPHI Worldwide," held in Frankfurt, Germany from October 28 to 30, where it promoted global partnerships and market expansion by showcasing its innovative formulation platforms and biosimilar technologies.

A view of the Daewoong Pharmaceutical booth at the world's largest pharmaceutical and biotechnology exhibition, "2025 CPHI Worldwide," held in Frankfurt, Germany from the 28th to the 30th of last month. Daewoong Pharmaceutical

At this exhibition, Daewoong Pharmaceutical pursued global contracts by highlighting its flagship new drugs such as Fexuclu and Enblo, as well as next-generation technologies including GLP-1 (glucagon-like peptide-1) microneedles and biosimilars. In particular, the company focused on building even stronger global partnerships based on the achievements made at CPHI 2024 in Milan last year.

One of the core technologies presented at this exhibition is the microneedle patch-based drug delivery platform. This technology enables a patch formulation that can replace subcutaneous injections, minimizing pain and allowing for self-administration, thereby improving patient compliance. Its bioavailability has recently been significantly enhanced, attracting strong interest from global partners.

This technology is currently being expanded from semaglutide (a GLP-1 analog) obesity treatments to growth hormones and botulinum toxin, with plans to further strengthen the foundation for global commercialization of innovative formulations across a wide range of disease areas in the future.

Additionally, Daewoong Pharmaceutical is intensively nurturing biosimilars as a next-generation core business. The company is developing a multifaceted business model targeting major advanced markets such as Europe and the United States, including global in-house development, joint development, licensing-in, and CDMO (Contract Development and Manufacturing Organization) collaborations.

Recently, Daewoong Pharmaceutical significantly strengthened its organizational capabilities by appointing Dr. Hong Seungseo, a leading expert in the biosimilar field, as Head of the BS Business Division. In the long term, the company is also pursuing a strategy to evolve its biosimilars into "biobetters" by integrating Daewoong's innovative formulation platforms.

Furthermore, Daewoong Pharmaceutical focused on expanding global partnerships in both advanced and emerging markets, including the United States, Europe, Central and South America, Russia, the Middle East, and Africa, based on its innovative new drugs such as Fexuclu (a treatment for gastroesophageal reflux disease) and Enblo (an SGLT-2 inhibitor diabetes treatment). These two innovative drugs are key product groups for realizing the "one product, one trillion won" strategy, and the company held active discussions with numerous countries and partners during the exhibition.

Daewoong Bio also operated a booth together with Daewoong Pharmaceutical, working to expand its global CDMO business and active pharmaceutical ingredient exports. Through meetings with 25 potential global CDMO clients, the company secured new customers and pursued an increase in active pharmaceutical ingredient exports worth approximately 17.4 billion KRW, while also strengthening its global manufacturing capabilities by diversifying its raw material supply chain and enhancing research capabilities.

Park Sungsoo, CEO of Daewoong Pharmaceutical, stated, "Our participation in this year's CPHI was a results-oriented exhibition where we went beyond simply promoting our technologies and engaged in concrete business discussions with global partners," adding, "We will accelerate our efforts to target the global healthcare market by leveraging future growth engines such as innovative microneedle-based formulations and biosimilars."